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We agree with Schwartz and Landrigan that 
there is a need for change in the regulatory 
system for chemicals used in products in the 
United States. Bisphenol A (BPA) is one of 
thousands of chemicals of concern, but it 
provides a striking example of what happens 
when there is no requirement for premarket 
testing. Full estrogenic activity was demon-
strated for BPA when it was tested for use 
as a pharmaceutical drug in 1936, which 
should have precluded its use in the wide 
range of products that results in continuous 
exposure (Stahlhut et al. 2009). The find-
ings we reported in our article (Taylor et al. 
2011) show that clearance of BPA in mice, 
monkeys, and humans does not differ, and 
years of research has demonstrated that mice 
and rats are valid models for predicting the 
long-term adverse consequences of develop-
mental exposure to estrogenic chemicals. A 
vast and rapidly growing number of stud-
ies with experi  mental animals (Richter et al. 
2007) and humans (Braun and Hauser 2011) 
report adverse effects later in life as a result of 
exposure to BPA during development.
In the 2003–2004 National Health and 
Nutrition Examination Survey (NHANES) 
study, the Centers for Disease Control and 
Prevention estimated that 93% of people in 
the United States are exposed to BPA, with 
higher exposures in children than adults. 
The potential exposure of fetuses and infants 
to BPA is especially concerning because 
BPA is not metabolized effectively dur-
ing these highly sensitive stages of human 
development. Our data (Taylor et al. 2011) 
indicate that to reach the median serum 
levels of unconjugated (bioactive) BPA 
reported in multiple biomonitoring studies 
(Vandenberg et al. 2010), exposure must 
be far higher than predicted by the Food 
and Drug Administration (FDA) based on 
its risk assessment of BPA (FDA 2008); 
these govern  ment estimates (FDA 2008) are 
based on kinetics after acute oral exposure 
and the assumption that food and beverage 
packaging is the only source of BPA expo-
sure. However, data from the 2003–2004 
NHANES (Stahlhut et al. 2009) confirmed 
that BPA exposure is likely to be from mul-
tiple sources—including thermal receipt 
paper—and there is evidence that in adults 
different forms of exposure do not have the 
same meta  bolic profile (Sieli et al. 2011).
We find it disturbing that government 
agencies continue to argue that the public 
should not be concerned about BPA because 
daily exposures are below “safe” levels. This 
conclusion is based on flawed studies using 
outdated approaches. We agree with Schwartz 
and Landrigan that we have to stop repeat-
ing the same mistakes made previously with 
chemicals such as lead, for which, after 
decades of repeatedly lowering “safe” exposure 
estimates, the current predicted “safe” level is 
still above levels now known to cause adverse 
effects. For endocrine-disrupting chemicals 
there are no threshold doses below which 
exposures are safe (Sheehan 2006), a reality 
that regulators are unwilling to acknowledge.
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In his commentary, Weiss (2012) dis-
cusses results of the recent Food and Drug 
Administration (FDA) evaluation of the pos-
sible association between artificial food color 
additives (AFCs) and adverse behaviors in 
children, including those related to hyper-
activity. The stated aim of the commentary 
is “to examine the basis of the FDA’s posi-
tion, the elements of the review that led to its 
decision and that of the committee, and the 
reasons why this is an environmental issue.” 
In the commentary, however, a) the FDA’s 
petition review and safety assessment pro-
cesses are misconstrued; b) the range of nor-
mal behaviors and the levels at which these 
behaviors can be considered adverse are not 
distinguished, and comparisons that cloud 
the distinction are unsupported; c) exam-
ples from individual studies are used out of 
context or irrespective of the conclusions 
expressed by the authors; d) specific results 
are cited from studies the FDA concluded 
were fundamentally flawed; and e) compre-
hensive reviews by other scientific panels are 
not mentioned. As a result, the viewpoint 
presented does not properly characterize the 
public health issue, the FDA’s evaluation 
and conclusions, or the processes involved, 
including the FDA’s proposed actions. This 
letter addresses as many general errors, omis-
sions, and apparent flaws in the commentary 
as space permits. 
In 2008, the Center for Science in the 
Public Interest (CSPI) petitioned the FDA 
to ban eight AFCs based primarily on results 
from clinical challenge studies on behavioral 
effects of these chemicals in children with a 
history of hyper  activity disorders or related 
behavioral problems (CSPI 2008). The peti-
tion also cited studies that tested potential Correspondence
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effects of AFCs in children without behav-
ioral problems (e.g., McCann et al. 2007) 
or assessed the effects of the Feingold diet, 
which eliminates more than just AFCs (e.g., 
Conners et al. 1976; Harley et al. 1978). 
In direct response to the petition and based 
on the breadth of the literature cited, the 
FDA assessed not only the hypothesis that 
AFCs trigger or exacerbate “hyperactivity” 
and attention deficit/hyper  activity dis  order 
(ADHD), as noted in the commentary, 
but rather considered all treatment-related 
behavioral effects from relevant clinical 
studies on AFCs. This was stated in direct 
and unequivocal language in the FDA’s 
Food Advisory Committee (FAC) meeting 
notice in the Federal Register (FDA 2010): 
The FAC’s agenda was “to discuss whether 
available relevant data demon  strate a link 
between children’s consumption of synthetic 
color additives in food and adverse effects on 
behavior,” and that is how the committee 
considered the matter at the meeting. 
As understood and incorporated in the 
FDA petition review process, confidence in 
the reliability of a study’s findings must be 
determined through scientific review using 
appropriate criteria before proper interpreta-
tion and applicability can be determined. 
Only then can results be considered in the 
context of all studies reviewed and a final 
comprehensive interpretation rendered. 
Using data out of context of study design 
and without regard to reliability and sound 
interpretation result in improper charac-
teriza  tion of the issue and misdirection for 
future research. For example, Weiss (2012) 
stated that the McCann et al. (2007) study 
“demonstrated statistically significant 
adverse responses in both groups of chil-
dren to the food color challenge.” Several 
uncertainties in that study stemming from 
issues and confounders related to study 
design and outcome measures were not men-
tioned, such as a) inclusion of a preservative 
(sodium benzoate) and different challenge 
color mixes in the two age groups of chil-
dren; b) inconsistencies between parental 
observations and clinical or teacher obser-
vations; and c) charac  terization of a treat-
ment effect as adverse when it may, in fact, 
fall within the normal range of childhood 
behavior. The evaluations of the McCann 
study by both the FDA and the European 
Food Safety Authority (EFSA 2008) consid-
ered it equivocal and of uncertain biological 
relevance. In the commentary, effect size is 
cited in support of the over  interpretation of 
the inconclusive results. This point ignores 
differences in nature and magnitude of an 
end point when comparing effect sizes. The 
examples of respiratory infection and dimin-
ished intelligence quotient (IQ) included in 
the commentary have narrow normal ranges; 
by contrast, altered behavioral activity has 
a much wider range, including levels of ele-
vated activity not considered adverse, but in 
the range of normal activity for children. 
In the commentary (Weiss 2012), there 
was no mention of the FDA’s conclusion 
that “Exposure to food and food compo-
nents, including [AFC] and preservatives, 
may be associated with adverse behaviors, 
not necessarily related to hyper  activity, in 
certain susceptible children with ADHD and 
other problem behaviors, and possibly in 
susceptible children from the general popu-
lation” (FDA FAC 2011a) is in agreement 
with two published meta-analysis studies, 
Schab and Trinh (2004) and Kavale and 
Forness (1983), as well as earlier conclu-
sions of a 1982 National Institutes of Health 
(NIH) expert review panel (NIH 1982).
The FDA’s comprehensive literature 
review and weight-of-evidence analysis of the 
data to date support the conclusion that 
Food-related triggering of problem behaviors is 
not due to an inherent neurotoxic property of the 
food or food components, including any of the 
artificial food colors and preservatives, but appears 
to result from a unique intolerance exhibited by 
certain predisposed children to a variety of food 
items and color additives. (FDA FAC 2011a)
According to Weiss (2012), this con-
clusion suggests that “the central nervous 
system is not the essential substrate for 
behavior or that behavior is a phenomenon 
independent of the brain.” The commentary 
is incorrect; the FDA’s conclusion is that 
the evidence suggests that certain food com-
ponents, including AFCs, do not appear to 
have inherent neuro  toxic properties but that 
some neuro  biologic and/or immuno  logic 
properties of a subpopulation predispose the 
group to have an intolerance to specific food 
items, resulting in a behavioral response. 
These responses can vary between individuals 
in nature, magnitude, and triggering item. 
In contrast to the inference in the com-
mentary, the FDA’s evaluation (FDA FAC 
2011a) also proposed the need for research 
to charac  terize the underlying properties of 
this sensitivity so that any potentially vulner-
able subpopulation can be clearly identified 
and any appropriate additional steps can be 
taken to ensure that the group is protected.
In his commentary, Weiss (2012) also 
erroneously stated that the “FDA reviewed 
the available evidence and concluded that it 
did not warrant further agency action.” The 
FDA has not reached any such conclusion. 
The FDA is reviewing recommendations 
made by the FAC, as well as public com-
ments submitted in response to the meeting, 
including issues presented in the commen-
tary, as we continue our review of the infor-
mation and decide how to move forward on 
this matter.
I hope that this letter helps to clarify the 
FDA’s evaluation and position with regard 
to the possible association between AFCs 
and problem behaviors in children, includ-
ing those related to hyper  activity. Any party 
interested in further clarification of the FDA’s 
evaluation, the CSPI petition review, and the 
FAC can access relevant, detailed information 
online from the FAC (FDA FAC 2011b). 
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